Suchergebnisse - "Fakih, Marwan G"

PubPharm (14)

1

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

enthalten in: The New England journal of medicine | 2023

von Fakih, M. | Salvatore, L. | Esaki, T. | +16

2

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer : A Randomized Clinical Trial

enthalten in: JAMA network open | 2022

von Mettu, N. | Ou, F. | Zemla, T. | +13

3

Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer

enthalten in: The oncologist | 2018

von Fakih, M.

4

A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan

enthalten in: Oncology | 2013

von Fora, A. | McMahon, J. | Wilding, G. | +4

5

Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer

enthalten in: Clinical colorectal cancer | 2012

von Carneiro, B. | Ramanathan, R. | Fakih, M. | +9

6

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2010

von Reidy, D. | Vakiani, E. | Fakih, M. | +11

7

Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer

enthalten in: Oncology | 2010

von Vaidyanathan, G. | Groman, A. | Wilding, G. | +1

8

A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer

enthalten in: Critical reviews in oncology/hematology | 2009

von Puthillath, A. | Mashtare, T. | Wilding, G. | +6

9

Neoadjuvant chemoradiation for rectal cancer : is more better?

enthalten in: Oncology (Williston Park, N.Y.) | 2008

von Patel, A. | Puthillath, A. | Yang, G. | +1

10

Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab

enthalten in: Clinical colorectal cancer | 2007

von Gupta, B. | LeVea, C. | Litwin, A. | +1